Speciallægeselskabet Reumatologisk Klinik Brønshøj ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.9% 2.0% 1.4% 1.3% 1.7%  
Credit score (0-100)  72 71 78 79 72  
Credit rating  A A A A A  
Credit limit (kDKK)  0.8 0.4 24.7 58.3 3.7  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Gross profit  2,937 2,798 2,799 2,686 1,989  
EBITDA  295 272 651 865 1,006  
EBIT  166 144 523 737 878  
Pre-tax profit (PTP)  160.3 143.0 519.6 728.2 863.7  
Net earnings  125.1 111.3 405.0 567.8 672.3  
Pre-tax profit without non-rec. items  160 143 520 728 864  

 
See the entire income statement

Balance sheet (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  96.0 72.0 48.0 24.0 0.0  
Shareholders equity total  1,553 1,557 1,762 2,130 2,687  
Interest-bearing liabilities  0.0 34.4 0.0 0.0 0.0  
Balance sheet total (assets)  2,056 2,050 2,630 2,604 2,976  

Net Debt  -1,019 -1,064 -1,808 -1,948 -2,461  
 
See the entire balance sheet

Volume 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,937 2,798 2,799 2,686 1,989  
Gross profit growth  0.0% -4.7% 0.0% -4.0% -26.0%  
Employees  1 2 2 2 1  
Employee growth %  0.0% 66.7% 0.0% 0.0% -40.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,056 2,050 2,630 2,604 2,976  
Balance sheet change%  0.0% -0.3% 28.3% -1.0% 14.3%  
Added value  166.4 144.3 523.4 737.0 878.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  592 -256 -256 -256 -256  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  5.7% 5.2% 18.7% 27.4% 44.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  8.1% 7.0% 22.4% 28.2% 31.5%  
ROI %  10.7% 8.1% 27.6% 37.6% 36.3%  
ROE %  8.1% 7.2% 24.4% 29.2% 27.9%  

Solidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  75.6% 76.0% 67.0% 81.8% 90.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -346.1% -390.8% -277.5% -225.2% -244.5%  
Gearing %  0.0% 2.2% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 7.1% 21.9% 0.0% 0.0%  

Liquidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  2.6 0.0 2.5 4.8 9.9  
Current Ratio  2.6 0.0 2.5 4.8 9.9  
Cash and cash equivalent  1,019.4 1,098.7 1,807.5 1,948.1 2,460.7  

Capital use efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  811.4 1,428.4 1,279.3 1,775.9 2,461.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  139 72 262 368 732  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  245 136 326 433 839  
EBIT / employee  139 72 262 368 732  
Net earnings / employee  104 56 202 284 560